PT1109571E - Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos - Google Patents

Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos

Info

Publication number
PT1109571E
PT1109571E PT99968631T PT99968631T PT1109571E PT 1109571 E PT1109571 E PT 1109571E PT 99968631 T PT99968631 T PT 99968631T PT 99968631 T PT99968631 T PT 99968631T PT 1109571 E PT1109571 E PT 1109571E
Authority
PT
Portugal
Prior art keywords
methods
compositions
hypertension
treatment
factor
Prior art date
Application number
PT99968631T
Other languages
English (en)
Portuguese (pt)
Inventor
George F Schreiner
Richard J Johnson
Original Assignee
Scios Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc, Univ Washington filed Critical Scios Inc
Publication of PT1109571E publication Critical patent/PT1109571E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT99968631T 1998-09-09 1999-09-09 Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos PT1109571E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27

Publications (1)

Publication Number Publication Date
PT1109571E true PT1109571E (pt) 2004-05-31

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
PT99968631T PT1109571E (pt) 1998-09-09 1999-09-09 Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
PT99946776T PT1112083E (pt) 1998-09-09 1999-09-09 Uso de um factor angiogenico para o tratamento de angiopatias microvasculares

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT99946776T PT1112083E (pt) 1998-09-09 1999-09-09 Uso de um factor angiogenico para o tratamento de angiopatias microvasculares

Country Status (13)

Country Link
US (3) US6352975B1 (cg-RX-API-DMAC7.html)
EP (2) EP1112083B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002532382A (cg-RX-API-DMAC7.html)
AT (2) ATE253934T1 (cg-RX-API-DMAC7.html)
AU (2) AU5910599A (cg-RX-API-DMAC7.html)
BR (2) BR9913533A (cg-RX-API-DMAC7.html)
CA (2) CA2340728C (cg-RX-API-DMAC7.html)
DE (2) DE69912815T2 (cg-RX-API-DMAC7.html)
DK (2) DK1112083T3 (cg-RX-API-DMAC7.html)
ES (2) ES2211165T3 (cg-RX-API-DMAC7.html)
IL (2) IL141686A0 (cg-RX-API-DMAC7.html)
PT (2) PT1109571E (cg-RX-API-DMAC7.html)
WO (2) WO2000013702A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253934T1 (de) * 1998-09-09 2003-11-15 Scios Inc Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
JP2003513105A (ja) * 1999-11-02 2003-04-08 ジェネンテック・インコーポレーテッド eNOS活性の調節とその治療的使用
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU2002317333C1 (en) 2001-08-01 2009-06-25 University Of Bristol VEGF isoform
US7432301B2 (en) * 2001-08-20 2008-10-07 University Of Virginia Patent Foundation Use of S-nitrosothiol signaling to treat disordered control of breathing
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのRNAi治療用の組成物および方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
EP1964568B1 (en) * 2005-08-31 2014-03-26 National University Corporation Kagawa University Utilization of hypertension/hypercardia-preventing effect of d-allose
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
GB0921525D0 (en) 2009-12-08 2010-01-27 Isis Innovation Product and method
WO2018183625A1 (en) 2017-03-30 2018-10-04 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
ES2103740T3 (es) 1989-03-24 1997-10-01 Univ California Factor de crecimiento celular endotelialico, su aislamiento y su expresion.
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
AU729420B2 (en) * 1996-11-01 2001-02-01 Eurogene Limited Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
ATE253934T1 (de) * 1998-09-09 2003-11-15 Scios Inc Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien

Also Published As

Publication number Publication date
BR9913564A (pt) 2001-05-22
DK1109571T3 (da) 2004-06-21
EP1112083B1 (en) 2003-11-12
US20020193288A1 (en) 2002-12-19
WO2000013703A9 (en) 2000-06-02
ATE260675T1 (de) 2004-03-15
EP1109571A2 (en) 2001-06-27
CA2340728A1 (en) 2000-03-16
IL141686A0 (en) 2002-03-10
JP2002524421A (ja) 2002-08-06
CA2340728C (en) 2007-11-27
US6352975B1 (en) 2002-03-05
US20040224885A1 (en) 2004-11-11
ATE253934T1 (de) 2003-11-15
DE69912815T2 (de) 2004-10-21
DK1112083T3 (da) 2004-03-08
WO2000013703A2 (en) 2000-03-16
ES2216630T3 (es) 2004-10-16
EP1112083A2 (en) 2001-07-04
AU5910599A (en) 2000-03-27
DE69915310D1 (de) 2004-04-08
ES2211165T3 (es) 2004-07-01
CA2340320A1 (en) 2000-03-16
PT1112083E (pt) 2004-03-31
DE69912815D1 (de) 2003-12-18
CA2340320C (en) 2006-11-14
EP1109571B1 (en) 2004-03-03
IL141687A0 (en) 2002-03-10
WO2000013702A2 (en) 2000-03-16
WO2000013702A9 (en) 2000-10-19
DE69915310T2 (de) 2005-03-10
BR9913533A (pt) 2001-06-05
WO2000013702A3 (en) 2000-09-08
JP2002532382A (ja) 2002-10-02
WO2000013703A3 (en) 2000-07-06
AU6028599A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
BR9913564A (pt) Tratamento de angiopatias microvasculares
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
PL328858A1 (en) Immunogenous peptides
DK0912535T3 (da) Konjugater af cis-docosahexaensyre og paclitaxel
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
WO2003053383A3 (fr) Utilisation cosmetique d’au moins une hydrophobine pour le traitement des matieres keratiniques
PT1246835E (pt) Sapogeninas substituídas e sua utilização
BR0014381A (pt) Derivados de 5-beta-sapogenina e pseudossapogenina e seu uso no tratamento de demência
BR9912327A (pt) Inibidores da uroquinase
DK0967987T3 (da) Sammensætning til behandling af tumorer indeholdende hajbruskekstrakter og anitneoplastiske stoffer
TR199901104T2 (xx) Farmas�tik bile�ikler.
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
GB9923078D0 (en) Sapogenin derivatives and their use
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
ATE344664T1 (de) Verbesserte methode zur eradikation von helicobacter pylori
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
DK1303294T3 (da) Fremgangsmåde til behandling af instabil angina pectoris
DE69835828D1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
EP1447089A3 (en) Methods of treating hypertension and compositions for use therein
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
UA32314A (uk) Спосіб лікування некротичного панкреатиту
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin